Shares of PureTech Health plc (LON:PRTC – Get Free Report) rose 6.3% on Monday . The stock traded as high as GBX 127 ($1.67) and last traded at GBX 125.40 ($1.65). Approximately 1,234,305 shares changed hands during trading, an increase of 17% from the average daily volume of 1,059,029 shares. The stock had previously closed at GBX 118 ($1.56).
Analysts Set New Price Targets
Separately, Jefferies Financial Group restated a “buy” rating and set a GBX 455 ($6.00) price objective on shares of PureTech Health in a research report on Monday, December 16th.
Read Our Latest Research Report on PRTC
PureTech Health Trading Up 6.3 %
PureTech Health Company Profile
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Featured Stories
- Five stocks we like better than PureTech Health
- How to Invest in the Best Canadian Stocks
- Why NVIDIA Stock Could Soar Despite Wall Street Downgrades
- Earnings Per Share Calculator: How to Calculate EPS
- Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold
- 3 Dividend Kings To Consider
- 3 Hot New IPOs Defying the 2025 Market Slump
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.